Barry J.  Regan net worth and biography

Barry Regan Biography and Net Worth

EVP of DexCom
Barry Regan is Executive Vice President of Global Operations at Dexcom.

Barry joined Dexcom in 2020, and he is responsible for Dexcom’s global operations teams including Corporate Operations Engineering, Manufacturing, Supply Chain, Procurement, and Operations Program Management. Barry also oversees the manufacturing development, scale-up, and automation of Dexcom’s innovative Continuous Glucose Monitoring products.

With more than 25 years of experience in operations, Barry has led organizations in the global medical device and pharmaceutical industries through scaling and transformational change efforts to support growth and drive strategy.

Prior to Dexcom, Barry served as Senior Vice President of Global Operations at Wright Medical, leading global Manufacturing, Supply Chain, Engineering, Procurement, and Distribution and Logistics. Barry has also held leadership roles at Smith & Nephew, AbbVie, and Abbott Laboratories.

He holds a Bachelor of Technology degree in Operations Management and Electronic Engineering from the University of Limerick, Ireland, and a Master of Business Administration degree from Lake Forest Graduate School of Management.

What is Barry J. Regan's net worth?

The estimated net worth of Barry J. Regan is at least $7.49 million as of November 8th, 2023. Mr. Regan owns 64,250 shares of DexCom stock worth more than $7,494,120 as of June 19th. This net worth approximation does not reflect any other assets that Mr. Regan may own. Learn More about Barry J. Regan's net worth.

How do I contact Barry J. Regan?

The corporate mailing address for Mr. Regan and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Barry J. Regan's contact information.

Has Barry J. Regan been buying or selling shares of DexCom?

Barry J. Regan has not been actively trading shares of DexCom within the last three months. Most recently, Barry J. Regan sold 2,019 shares of the business's stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $95.22, for a transaction totalling $192,249.18. Following the completion of the sale, the executive vice president now directly owns 64,250 shares of the company's stock, valued at $6,117,885. Learn More on Barry J. Regan's trading history.

Who are DexCom's active insiders?

DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.

Are insiders buying or selling shares of DexCom?

During the last twelve months, insiders at the medical device company sold shares 39 times. They sold a total of 265,317 shares worth more than $34,660,713.42. The most recent insider tranaction occured on June, 14th when Director Bridgette P Heller sold 1,000 shares worth more than $113,550.00. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.

Information on this page was last updated on 6/14/2024.

Barry J. Regan Insider Trading History at DexCom

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/8/2023Sell2,019$95.22$192,249.1864,250View SEC Filing Icon  
3/13/2023Sell2,010$106.27$213,602.7070,472View SEC Filing Icon  
1/30/2023Sell2,213$106.12$234,843.5659,386View SEC Filing Icon  
3/29/2022Sell1,106$500.00$553,000.00View SEC Filing Icon  
12/13/2021Sell1,214$563.93$684,611.02View SEC Filing Icon  
See Full Table

Barry J. Regan Buying and Selling Activity at DexCom

This chart shows Barry J Regan's buying and selling at DexCom by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DexCom Company Overview

DexCom logo
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $116.64
Low: $116.13
High: $117.49

50 Day Range

MA: $126.16
Low: $113.81
High: $139.62

2 Week Range

Now: $116.64
Low: $74.75
High: $142.00


2,192,895 shs

Average Volume

2,732,992 shs

Market Capitalization

$46.39 billion

P/E Ratio


Dividend Yield